Abstract
The Tax protein encoded by human T cell leukemia virus type I transactivates the viral promoter by forming a complex with several cellular factors bound to three repeats of a specific upstream regulatory sequence. We have shown that transactivation by Tax was correlated with its ability to interact with the C-terminal moiety of the TATA box-binding protein (TBP). In the present study, the ability of Tax to interact with several human TBP-associated factors (TAFIIs) was analyzed. We show that Tax interacts selectively with hTAFII28 in transfected HeLa cells. A direct interaction between Tax and hTAFII28 was also observed in vitro with purified proteins. In transient expression studies we show that overexpression of hTAFII28 significantly increased transactivation by Tax, both in the absence and in the presence of overexpressed TBP. The ability of hTAFII28 to potentiate transactivation correlated with the ability of Tax to interact with hTAFII28 and also with the ability of hTAFII28 to interact with TBP. Coexpression of TBP and hTAFII28 resulted in an additive increase in transactivation by Tax. From these observations we propose that transcriptional activation by Tax involves multiple interactions with TFIID via its TBP and hTAFII28 subunits.
The viral protein Tax strongly activates transcription of the human T cell leukemia virus type I (HTLV-I) provirus and of a specific group of cellular genes (1). Various studies have established that Tax is recruited to the Tax-responsive element 1 of the HTLV-I promoter and to the serum-responsive element of the c-fos promoter (2–5) via interactions with cellular transcription factors. In agreement with this notion, a GAL4 DNA binding domain-Tax fusion protein stimulates transcription of a reporter gene under the control of GAL4 sites (6). Using this approach, we have shown that the transcriptional activity of the GAL4-Tax fusion protein involves a direct protein-protein interaction between Tax and TATA box-binding protein (TBP) (7).
However, in vitro transcription experiments have established that activation by Tax requires the transcription factor complex TFIID comprised of TBP and TBP-associated factors (TAFIIs) (8). To better understand the molecular mechanisms underlying activation by Tax, we investigated the interactions between Tax and hTAFIIs. These experiments show a selective interaction of Tax with hTAFII28. Increasing the intracellular concentration of hTAFII28 augments the activity of GAL4-Tax, and the overexpression of both TBP and hTAFII28 resulted in an additive increase in activation. The ability of hTAFII28 to potentiate activation by Tax was dependent on its ability to interact with TBP. These observations support the notion that Tax activates transcription by interacting with TFIID through both TBP and hTAFII28.
MATERIALS AND METHODS
Transfections.
HeLa cells and COS-7 cells, grown in monolayers to 40% (HeLa cells) or 80% (COS-7 cells) confluence, were transfected by the calcium phosphate coprecipitation method (7). The total amount of simian virus 40 promoter-containing plasmids was adjusted to a constant level with pSG5, and the total amount of cytomegalovirus promoter-containing plasmids was adjusted to a constant level with pXJ41.
Immunoprecipitations.
COS-7 cells extracts were prepared by three cycles of freeze-thaw in 100 μl of buffer A (50 mM Tris·HCl, pH 7.9/20% glycerol/1 mM dithiothreitol/0.1% Nonidet P-40) containing 250 mM KCl. After incubation for 30 min in ice, the extracts were centrifugated for 10 min at 10,000 × g. Supernatants were incubated with ≈0.5 μg of antibody for 30 min in ice. Protein G-Sepharose (30 μl) was added, and the mix was further incubated for 2 h at 4°C. The beads were washed four times with 1 ml of buffer A containing 500 mM KCl for 5 min at room temperature. The complexes were uncoupled from Sepharose beads by incubation at 90°C for 10 min in SDS/PAGE loading buffer. After migration through a SDS/10% protein gel, proteins were analyzed by immunoblotting using enhanced chemiluminescence detection (Amersham).
Chloramphenicol Acetyltransferase (CAT) Assays.
The level of CAT protein produced in transfected HeLa cells was measured using an ELISA (Boehringer Mannheim) that was performed according to the manufacturer’s instructions.
Expression of Recombinant Proteins and Protein Affinity Chromatography.
Glutathione S-transferase (GST)-Tax protein was produced in bacteria and coupled to glutathione agarose beads as described (7). The beads coupled to either GST or GST-Tax were incubated with purified TBP (9) and His-hTAFII28. His-hTAFII28 was purified by affinity on Ni2+-agarose beads (10, 11). Protein affinity chromatography was performed essentially as described (10). Similarly, GST-TBP was produced in bacteria from plasmid pGEX2T-TFIID and coupled to gluthatione Sepharose beads. Tax and hTAFII28 were produced and labeled with [35S]methionine using the TNT Coupled Reticulocyte Lysate system (Promega) with plasmids pSG-Tax and pXJ41-hTAFII28.
RESULTS
Interaction Between Tax and hTAFII28.
To investigate the possible contribution of hTAFIIs to activation by Tax, the ability of this transactivator to interact with several hTAFIIs was tested in coimmunoprecipitation experiments. HeLa cells were transfected with plasmid pSG-Tax alone or with vectors expressing hTAFII18, hTAFII20, hTAFII28, hTAFII30, hTAFII55, hTAFII100, hTAFIIΔN135, or hTAFII250 (12, 13). The amount of hTAFII expression vectors used in these experiments was adjusted to give similar amounts of each hTAFII as evaluated by immunoblotting with anti-hTAFII antibodies (data not shown). Transfected cell extracts were immunoprecipitated with mAbs directed against the corresponding hTAFIIs, and the precipitated proteins were analyzed by immunoblotting with a polyclonal antibody directed against Tax. In the absence of coexpressed hTAFIIs, Tax was not precipitated (Fig. 1 A and B, lanes 1, 3, and 5; Fig. 1C, lanes 1, 3, 5, and 7). In contrast, Tax was precipitated in the presence of coexpressed hTAFII28 (Fig. 1A, lane 6; Fig. 1B, lane 2; Fig. 1C, lane 2), and weaker interactions between Tax and both hTAFII100 and hTAFII250 also could be observed upon longer exposures of the blots (data not shown). These experiments show a selective interaction between Tax and hTAFII28. The ability of Tax to interact directly with hTAFII28 in vitro was tested, and this interaction was compared with that between Tax and TBP (7). Purified hTAFII28 (His-tagged) and TBP were incubated with GST-Tax fusion protein coupled to agarose beads. The amounts of both hTAFII28 and TBP specifically bound by Tax were similar although slightly lower for hTAFII28 (Fig. 2A, lanes 4 and 6). The same experiment performed with hTAFII28 and TBP produced and radioactively labeled by in vitro translation showed that Tax retained comparable amounts of both proteins (data not shown). These experiments clearly indicated that Tax binds specifically hTAFII28 and that this binding does not depend on a bridging factor. The ability of TBP, hTAFII28, and Tax to form a ternary complex also was tested. Radiolabeled Tax and hTAFII28 were incubated with immobilized GST-TBP. The GST-TBP was then eluted with free gluthatione, and both Tax and hTAFII28 were present in the eluate (Fig. 2B, lane 2). The eluted proteins were then immunoprecipitated with the anti-Tax antibody. Both Tax and hTAFII28 were immunoprecipitated, clearly showing that hTAFII28 also was associated with the Tax-TBP complex (Fig. 2B, lane 3). This in vitro experiment establishes that TBP, hTAFII28, and Tax form a ternary complex.
Transactivation by Tax Is Augmented by Overexpression of hTAFII28.
To address the functional significance of the Tax-hTAFII28 interaction, the effect of an increase in the intracellular hTAFII28 concentration on transcriptional activation by Tax was evaluated. As controls, the effects of coexpression of hTAFII55, hTAFII100, and hTAFIIΔN135 that either do not, or only weakly, interact with Tax also were tested. In the absence of overexpression of TBP, hTAFII28 stimulated the activity of the GAL4-Tax fusion protein (Fig. 3, lanes 2 and 4), whereas expression of the other hTAFIIs did not significantly affect its activity (Fig. 3, lanes 6, 8, and 10). As reported, overexpression of TBP also increased the activity of GAL4-Tax (Fig. 3, lanes 2 and 12). In the presence of coexpressed TBP, expression of hTAFII28 again increased activation by GAL4-Tax, resulting in an additive effect of TBP and hTAFII28 (Fig. 3, lanes 2, 4, 12, and 14). Expression of hTAFII100 that interacted weakly with Tax also mildly potentiated activation when coexpressed with TBP, but no significant effect was seen with hTAFII55 or hTAFIIΔN135 (Fig. 3, lanes 16, 18, and 20).
It has been observed that activation is diminished when elevated amounts of the GAL4-Tax expression vector are transfected (7). This self-interference (squelching) effect is interpreted as the titration of a limiting factor playing a key role in the transactivation process by the excess of GAL4-Tax. This squelching effect can be partially alleviated by overexpression of TBP, supporting the notion that TBP may be one of the limiting targets for Tax. The ability of TBP to alleviate squelching was correlated with a direct protein-protein interaction between Tax and TBP (7). The ability of overexpressed hTAFII28 to alleviate GAL4-Tax self-interference was also examined. As observed for TBP, overexpression of hTAFII28 was able to partially alleviate the squelching seen with elevated levels of GAL4-Tax (Fig. 4). No such effect was observed with other hTAFIIs (data not shown) or TFIIB (7). As observed for transactivation, the reversal of squelching by the combination of hTAFII28 and TBP was additive over a large range of GAL4-Tax concentrations (Fig. 4). At optimal concentrations of GAL4-Tax overexpression of both TBP and hTAFII28 resulted in a very potent 40-fold increase in activation by the GAL4-Tax protein. These experiments indicate that hTAFII28 is also a limiting factor for transactivation by Tax.
To further correlate the Tax-hTAFII28 interaction with the ability of overexpressed hTAFII28 to modulate activation by Tax, mutants of Tax were tested for their ability to interact with hTAFII28. Three Tax mutants that are defective for transactivation of the HTLV-I promoter were tested. Mutations M5 (18) and M137 (19) markedly reduced association with hTAFII28 as evaluated in coimmunoprecipitation experiments (Fig. 5A, lanes 2, 3, and 5) whereas mutation M15 (18) did not affect interaction with hTAFII28 (Fig. 5A, lanes 2 and 4). The effect of the overexpression of hTAFII28, and/or TBP on activation by these three Tax mutants was tested. Overexpression of TBP rescued activation by GAL4-Tax M5, but overexpression of hTAFII28 did not significantly affect its activity in either the presence or absence of TBP (Fig. 5B, lanes 2–5). In contrast, overexpression of hTAFII28 had a moderate positive effect on the activity of GAL4-Tax M15 (Fig. 5B, lanes 6 and 7) and TBP had a lesser effect (Fig. 5B, lane 8). However, overexpression of both hTAFII28 and TBP rescued partially the phenotype of this mutant (Fig. 5B, lane 9). The activity of GAL4-Tax M137 could not be rescued by TBP, hTAFII28, or a combination of both (Fig. 5B, lanes 10–13). Thus, mutation M5, which only partially impairs interaction with TBP (7), is corrected, at least to some extent, by overexpression of TBP but is insensitive to overexpression of hTAFII28 in agreement with the loss of interaction with this hTAFII. On the other hand, mutation M15, whose phenotype was rescued inefficiently by TBP overexpression when compared with mutation M5, was efficiently rescued by overexpression of both hTAFII28 and TBP. This shows that these two factors can cooperate together to rescue the phenotype of a negative mutation that preserves the capacity to interact with hTAFII28. In contrast, mutation M137, which disrupts interaction with hTAFII28, was insensitive to overexpression of either hTAFII28 or TBP, as well as to the combination of both factors. These results illustrate that both TBP and hTAFII28 participate in the transactivation by Tax. They also indicate that the ability of hTAFII28 overexpression to increase the activity of Tax is correlated with the ability of both proteins to interact.
Potentiation of Activation by Tax Requires hTAFII28-TBP Interaction.
It has been shown that hTAFII28 directly interacts with TBP (10, 12). Consequently, we asked whether hTAFII28 has to interact with TBP to augment activation by Tax. To answer this question, two mutants of hTAFII28 that are unable to interact with TBP were analyzed. The two mutations correspond to a deletion of the N-terminal 63 amino acids [hTAFII28(64–211)] and to a substitution of three glutamic acidic residues [hTAFII28(1–179)M1], which probably disrupts a putative amphipathic α-helical motif located between amino acids 161 and 179 in the context of a C-terminally truncated hTAFII28 (12). Coimmunoprecipitation experiments showed that these two mutants were still able to bind Tax (Fig. 6A, lanes 2–4). The interaction of Tax with hTAFII28(1–179)M1 was in fact stronger than with wild type (Fig. 6A, lanes 2 and 3). The effect of expression of these mutants on the activity of the wild-type GAL4-Tax protein was examined in both the presence and the absence of overexpressed TBP. Although wild-type hTAFII28(1–211) potentiated the activity of GAL4-Tax in both the absence and presence of coexpressed TBP, the mutants that are unable to associate with TBP no longer exerted a functional effect on transcriptional activation by Tax (Fig. 6C, lanes 2, 4, 6, 8, 10, 12, 14, and 16). As indicated by the immunoprecipitation experiment, the lack of functional effect could not be attributed to a lack of expression of these two mutants (Fig. 6B, lanes 2, 3 and 4). These results indicate that hTAFII28 must interact with TBP to participate in the transcriptional activation effect of Tax.
Cooperative Effect of TBP and hTAFII28 in the Tax Transactivation of the Entire HTLV-I Promoter.
To examine further the role of hTAFII28 in transcriptional activation by Tax, experiments were performed with the entire HTLV-I promoter. To distinguish the effect of the endogenous TFIID from that induced by the transfection of expression vectors, TBP bearing the spm3 mutation was used (20, 21). This mutant binds to both TATAAAA and TGTAAAA motifs whereas wild-type TBP recognizes only the former. The TATA box of the HTLV-I promoter fused to CAT was changed to TGTAAAA. This mutation drastically reduced transactivation of this promoter by Tax (Fig. 7, lanes 2 and 4). Overexpression of hTAFII28 alone did not significantly restore transactivation (Fig. 7A, lanes 4 and 6). In contrast, expression of TBP spm3 alone rescued transactivation to some extent (Fig. 7A, lane 8), but, when expressed in combination with hTAFII28, significantly higher levels of transactivation were observed (Fig. 7A, lane 10). It is interesting to note that a clear positive effect of hTAFII28 was observed at intermediate levels of TBP spm3 overexpression, but when TBP spm3 was present in large excess, the amount of transcription observed was higher and the effect of hTAFII28 was less pronounced (data not shown). These observations support the notion that hTAFII28 and TBP cooperate to mediate Tax activation of the HTLV-I promoter.
DISCUSSION
Functional Interaction of Tax with hTAFII28.
We have analyzed the interaction between Tax and a series of human TAFIIs: hTAFII18, hTAFII20, hTAFII28, hTAFII30, hTAFII55, hTAFII100, hTAFIIΔN135, and hTAFII250. Immunoprecipitation experiments with similar amounts of these hTAFIIs show that the strongest interaction takes place between Tax and hTAFII28, weaker interactions being observed with hTAFII100 and hTAFII250. The results of in vitro interaction assays with recombinant proteins establish that the interaction between Tax and hTAFII28 is direct and does not depend on an additional bridging factor.
Our present results suggest that not only does Tax interact directly with hTAFII28 but that this interaction is critical for activation by Tax in vivo. This idea is supported by several observations. An increase in the intracellular concentration of hTAFII28 augments transactivation by Tax. This effect also was clearly seen in COS-7 cells (G.M. and A.R., unpublished results) that have low levels of endogenous TAFII28 (12). This positive effect was additive with that of overexpressed TBP and was most pronounced with higher concentrations of the pSG4-Tax expression vector, in which hTAFII28 and TBP overexpression alleviates Tax self-squelching, resulting in a 40-fold increase in activation. These in vivo results raise questions concerning the precise molecular mechanisms by which the overexpressed TBP and/or hTAFII28 act to increase activation by Tax in HeLa cells where TFIID complexes comprising hTAFII28 are present. TBP is present in various complexes permitting transcription by all three cellular RNA polymerases (22). The observation that mutations in TBP affecting its ability to promote transcription by RNA polymerase III cause an increase in expression of several genes transcribed by RNA polymerase II (23) strongly suggests that TBP is a limiting factor in the living cell. Therefore, it is likely that overexpressed TBP raises this concentration, at least to some extent, until the hTAFIIs become limiting. Similarly, an increase in the concentration of hTAFII28, which binds directly to TBP, may compete with the TAFIs and TAFIIIs and drive more TBP into the formation of a TFIID complex interacting with Tax. According to this model, overexpression of both TBP and hTAFII28 would most efficiently raise the concentration of TFIID complexes capable of functioning with Tax.
TBP and hTAFII28 also cooperate to allow Tax activation of the entire HTLV-I promoter and to partially rescue the phenotype of Tax mutants that had impaired ability to activate transcription. Strikingly, for two of these mutants, the loss of activation correlated with the loss of interaction with hTAFII28. The ability of hTAFII28 to increase Tax transactivation was not observed with hTAFII28 mutants that had diminished ability to interact with TBP. Together these results indicate that the Tax-hTAFII28, Tax-TBP, and TBP-hTAFII28 interactions participate to activation by Tax.
TFIID Is the Target of Tax in the Pre-Initiation Complex (PIC).
TFIID subunits are not the only components of the general transcription machinery that interact with transactivators. Interactions between activators and TFIIA, TFIIB, TFIIF, and TFIIE have been reported (24–28). We also have investigated the ability of Tax to interact in vitro with several general transcription factors. No interactions were detected with TFIIB (7), TFIIE, TFIIF, or TFIIH (R. Rousset, personal communication), and although we did detect an interaction with the precursor of the largest subunits of TFIIA, as recently reported (29), in transient transfection experiments the overexpression of the TFIIA subunits only slightly reduced the activity of the HTLV-I promoter activated by Tax (C.C., unpublished results). Thus, although TFIIA may be a further target of Tax, it appears that TFIID, via hTAFII28 and TBP, may be the principle general transcription factor targeted by Tax in vivo. However, it is possible that other TAFs, not assayed here, or other cofactors that may associate with the TBP-hTAFII28 complex participate in transactivation by Tax.
In the context of the natural HTLV-I promoter, TFIIB is probably also an important target. Kwok et al. (26) recently reported that the CREB binding protein (CBP) is recruited by Tax to the complex formed on the Tax-responsive element (30). Conversely, CBP recruits Tax to complexes formed by the binding of protein kinase A phosphorylated-CREB to cellular cAMP-responsive elements (30), thus augmenting transactivation by CREB. CBP protein has been reported to interact with TFIIB (26) and CREB with dTAFII110 (31), so the full complex of CREB, CBP and Tax could then potentially interact with multiple components of the general transcription machinery possibly explaining the functional cooperativity seen with these proteins.
hTAFII28 as a Regulatory TAF.
Recent advance in the understanding of the general arrangement of the TAFs has led to the proposal of a model in which hTAFII15/22, hTAFII31, and hTAFII81 assemble into a nucleosome like structure (32, 33). The other hTAFIIs would contact this core structure and ensure the contact with the activators. Our previous and present results indicate that hTAFII28, like hTAFII55, is one of the hTAFIIs involved in mediating the effect of transactivators. An interesting analogy can be noted in the two instances in which hTAFII28 has been implicated as a transcriptional coactivator. Although hTAFII28 potentiated the activity of the activation function-2 of several nuclear receptors, it did not interact directly with these nuclear receptors. This observation prompted us to suggest that hTAFII28 exerted its effect on activation function-2 by interacting with transcriptional intermediary factors that themselves interact with the nuclear receptors (12). Tax can in fact be considered as a virally encoded equivalent of these transcriptional intermediary factors, which acts as a bridging factor between CREB and possibly also p67SRF and the hTAFII28-TBP complex.
In conclusion, our results strengthen the notion that Tax exerts it transcriptional activity by establishing a direct protein-protein interaction with TFIID. The association between Tax and this general transcription factor is probably permitted by a dual interaction with both TBP and hTAFII28. Like several other viral transcriptional activators, Tax binds directly proteins participating to the assembly of the PIC. The additional ability of this protein to associate with different upstream factors bound to DNA explains that this single molecule is able to modify selectively a specific group of cellular promoters probably to create favorable conditions to the replication of the virus.
Acknowledgments
We thank J.-M Egly and V. Moncollin for TBP purified protein, N. Burton for plasmid pGEX2T-TFIID, and B. Cullen for the Tax antibody. This work was supported by grants from the Agence Nationale de Recherches sur le SIDA, the Centre National de la Recherche Scientifique, the Institut National de la Santé et de la Recherche Médicale, the Centre Hospitalier Universitaire Régional, the Ministère de la Recherche et de la Technologie, the Association pour la Recherche contre le Cancer and the Collège de France.
ABBREVIATIONS
- TBP
TATA box-binding protein
- TAF
TBP-associated factors
- GST
glutathione S-transferase
- HTLV-I
human T cell leukemia virus type I
- CREB
cAMP-responsive element binding protein
- CBP
CREB binding protein
- CAT
chloramphenicol acetyltransferase
- PIC
pre-initiation complex
References
- 1.Yoshida M. J Acquired Immune Defic Syndr. 1996;13:S63–S68. doi: 10.1097/00042560-199600001-00012. [DOI] [PubMed] [Google Scholar]
- 2.Béraud C, Lombard-Platet G, Michal Y, Jalinot P. EMBO J. 1991;10:3795–3803. doi: 10.1002/j.1460-2075.1991.tb04949.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Fujii M, Tsuchiya H, Chuhjo T, Akizawa T, Seiki M. Genes Dev. 1992;6:2066–2076. doi: 10.1101/gad.6.11.2066. [DOI] [PubMed] [Google Scholar]
- 4.Suzuki T, Fujisawa J-I, Toita M, Yoshida M. Proc Natl Acad Sci USA. 1993;90:610–614. doi: 10.1073/pnas.90.2.610. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Suzuki T, Hirai H, Fujisawa J-I, Fujita T, Yoshida M. Oncogene. 1993;8:2391–2397. [PubMed] [Google Scholar]
- 6.Fujisawa J-I, Toita M, Yoshimura T, Yoshida M. J Virol. 1991;65:4525–4528. doi: 10.1128/jvi.65.8.4525-4528.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Caron C, Rousset R, Béraud C, Moncollin V, Egly J-M, Jalinot P. EMBO J. 1993;12:4269–4278. doi: 10.1002/j.1460-2075.1993.tb06111.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Duvall J F, Kashanchi F, Cvekl A, Radonovich M F, Piras G, Brady J N. J Virol. 1995;69:5077–5086. doi: 10.1128/jvi.69.8.5077-5086.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Moncollin V, Schaeffer L, Chalut C, Egly J-M. Protein Expression Purif. 1992;3:374–379. doi: 10.1016/s1046-5928(05)80038-5. [DOI] [PubMed] [Google Scholar]
- 10.Mengus G, May M, Jacq X, Staub A, Tora L, Chambon P, Davidson I. EMBO J. 1995;14:1520–1531. doi: 10.1002/j.1460-2075.1995.tb07138.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Jacq X, Brou C, Lutz Y, Davidson I, Chambon P, Tora L. Cell. 1994;79:107–117. doi: 10.1016/0092-8674(94)90404-9. [DOI] [PubMed] [Google Scholar]
- 12.May M, Mengus G, Lavigne A-C, Chambon P, Davidson P. EMBO J. 1996;15:3093–3104. [PMC free article] [PubMed] [Google Scholar]
- 13.Dubrowskaya V, Lavigne A-C, Davidson I, Acker J, Staub A, Tora L. EMBO J. 1996;15:3702–3712. [PMC free article] [PubMed] [Google Scholar]
- 14.Crenon I, Béraud C, Simard P, Montagne J, Veschambre P, Jalinot P. Oncogene. 1993;8:867–875. [PubMed] [Google Scholar]
- 15.Lavigne A-C, Mengus G, May M, Dubrovskaya V, Tora L, Chambon P, Davidson I. J Biol Chem. 1996;271:19774–19780. doi: 10.1074/jbc.271.33.19774. [DOI] [PubMed] [Google Scholar]
- 16.Hanly S M, Rimsky L T, Malim M H, Kim J H, Hauber J, Duc-Dodon M, Le S Y, Maizel J V, Cullen B R, Greene W C. Genes Dev. 1989;3:1534–1544. doi: 10.1101/gad.3.10.1534. [DOI] [PubMed] [Google Scholar]
- 17.Harlow E, Lane D. Antibodies: A Laboratory Manual. Plainview, NY: Cold Spring Harbor Lab. Press; 1988. pp. 447–470. [Google Scholar]
- 18.Smith M R, Greene W C. Genes Dev. 1990;4:1875–1885. doi: 10.1101/gad.4.11.1875. [DOI] [PubMed] [Google Scholar]
- 19.Yamaoka S, Inoue H, Sakurai M, Sugiyama T, Hazama M, Yamada T, Hatanaka M. EMBO J. 1996;15:873–887. [PMC free article] [PubMed] [Google Scholar]
- 20.Keaveney M, Berkenstam A, Feigenbutz M, Vriend G, Stunneberg H G. Nature (London) 1993;365:562–565. doi: 10.1038/365562a0. [DOI] [PubMed] [Google Scholar]
- 21.Strubin M, Struhl K. Cell. 1992;68:721–730. doi: 10.1016/0092-8674(92)90147-5. [DOI] [PubMed] [Google Scholar]
- 22.Struhl K. Science. 1994;263:1103–1104. doi: 10.1126/science.8108728. [DOI] [PubMed] [Google Scholar]
- 23.Cormack B P, Struhl K. Science. 1993;262:244–248. doi: 10.1126/science.8211143. [DOI] [PubMed] [Google Scholar]
- 24.Lin Y-S, Green M R. Cell. 1991;64:971–981. doi: 10.1016/0092-8674(91)90321-o. [DOI] [PubMed] [Google Scholar]
- 25.Lin Y-S, Ha I, Maldonado E, Reinberg D, Green M R. Nature (London) 1991;353:569–571. doi: 10.1038/353569a0. [DOI] [PubMed] [Google Scholar]
- 26.Kwok R P, Lundblad J R, Chrivia J C, Richards J P, Bachinger H P, Brennan R G, Roberts S G, Green M R, Goodman R H. Nature (London) 1994;370:223–226. doi: 10.1038/370223a0. [DOI] [PubMed] [Google Scholar]
- 27.Joliot V, Demma M, Prywes R. Nature (London) 1995;373:632–635. doi: 10.1038/373632a0. [DOI] [PubMed] [Google Scholar]
- 28.Sauer F, Fondell J D, Ohkuma Y, Roeder R G, Jackle H. Nature (London) 1995;375:162–164. doi: 10.1038/375162a0. [DOI] [PubMed] [Google Scholar]
- 29.Clemens K E, Piras G, Radonovich M F, Choi K S, Duvall J F, DeJong J, Roeder R, Brady J N. Mol Cell Biol. 1996;16:4656–4664. doi: 10.1128/mcb.16.9.4656. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Kwok R P, Laurance M E, Lundblad J R, Goldman P S, Shih H-M, Connor L M, Marriott S J, Goodman R H. Nature (London) 1996;380:642–646. doi: 10.1038/380642a0. [DOI] [PubMed] [Google Scholar]
- 31.Ferreri K, Gill G, Montminy M. Proc Natl Acad Sci USA. 1994;91:1210–1213. doi: 10.1073/pnas.91.4.1210. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Xie X, Kokubo T, Cohen S L, Mirza U A, Hoffmann A, Chait B T, Roeder R G, Nakatani Y, Burley S K. Nature (London) 1996;380:316–322. doi: 10.1038/380316a0. [DOI] [PubMed] [Google Scholar]
- 33.Hoffmann A, Chiang C-M, Oelgeschläger T, Xie X, Burley S K, Nakatani Y, Roeder R G. Nature (London) 1996;380:356–359. doi: 10.1038/380356a0. [DOI] [PubMed] [Google Scholar]